肠道菌群与代谢手术治疗肥胖及其相关代谢性疾病的研究进展

doi:10.16352/j.issn.1001-6325.2026.02.0288

基础医学与临床 ›› 2026, Vol. 46 ›› Issue (2): 288-292.doi: 10.16352/j.issn.1001-6325.2026.02.0288

肠道菌群与代谢手术治疗肥胖及其相关代谢性疾病的研究进展

周健, 袁野^*

武汉科技大学附属武汉亚心总医院普外科,湖北武汉 430032

收稿日期:2025-03-12 修回日期:2025-05-27 出版日期:2026-02-05 发布日期:2026-01-21
通讯作者: ^* 93651434@qq.com
基金资助:
武汉市医学科研项目(WX21Q44)

Research progress on gut microbiota and metabolic surgery for the treatment of obesity and related metabolic diseases

ZHOU Jian, YUAN Ye^*

Department of General Surgery, Wuhan Asia General Hospital Affiliated to Wuhan University of Science and Technology, Wuhan 430042, China

Received:2025-03-12 Revised:2025-05-27 Online:2026-02-05 Published:2026-01-21
Contact: ^* 93651434@qq.com

摘要/Abstract

摘要： 肥胖及其相关代谢性疾病已成为全球重大健康挑战,传统疗法常存在疗效有限及易复发的缺陷。近年来,代谢手术作为治疗肥胖及其相关代谢疾病的重要手段,不仅能够显著减轻体质量,还在改善血糖水平、脂质代谢和降低心血管风险等方面表现出独特的疗效。代谢手术亦可改变肠道菌群的结构和功能,通过修复肠屏障功能、减少内毒素易位、抑制慢性炎性反应及调节代谢激素分泌,改善胰岛素敏感性和能量代谢平衡,在改善宿主代谢状态中起到关键作用。因此,本文对近年来关于肠道菌群与代谢手术在肥胖及其相关代谢性疾病中的研究进行综述,以期为开发新治疗策略提供思路。

关键词: 肠道菌群, 肥胖, 代谢手术, 代谢性疾病

Abstract: Obesity and its associated metabolic diseases have become significant global health challenges, with conventional therapies often limited by insufficient efficacy and high relapse rates. In recent years, metabolic surgery has emerged as a critical intervention for treating obesity and related metabolic disorders. Beyond achieving substantial weight loss, it demonstrates unique therapeutic benefits, including improvements in blood glucose levels, lipid metabolism, and reduced cardiovascular risk. Notably, metabolic surgery also alters the structure and function of the gut microbiota. These changes enhance host metabolic health by restoring intestinal barrier integrity, reducing endotoxin translocation, suppressing chronic inflammatory response, and regulating the secretion of metabolic hormones, thereby improving insulin sensitivity and energy homeostasis. Therefore, this paper provides a review of recent studies on the relationship between the intestinal microbiota and metabolic surgery in obesity and its related metabolic diseases, in order to provide new ideas for future treatment strategies.

Key words: gut microbiota, obesity, metabolic surgery, metabolic diseases

中图分类号:

R656.6

周健, 袁野. 肠道菌群与代谢手术治疗肥胖及其相关代谢性疾病的研究进展[J]. 基础医学与临床, 2026, 46(2): 288-292.

ZHOU Jian, YUAN Ye. Research progress on gut microbiota and metabolic surgery for the treatment of obesity and related metabolic diseases[J]. Basic & Clinical Medicine, 2026, 46(2): 288-292.

参考文献 25

[1]	Tham KW, Lim AYL, Baur LA, et al. The global agenda on obesity: what does this mean for Singapore?[J]. Sngapore Med J, 2023, 64: 182-187.
[2]	Rhee EJ. The influence of obesity and metabolic health on vascular health[J]. Endocrinol Metab (Seoul), 2022, 37: 1-8.
[3]	Golzarand M, Toolabi K, Douraghi M, et al. Changes in the gut microbiota composition and their relation to dietary intake after bariatric surgery[J]. Obes Surg, 2023, 33: 2866-2873.
[4]	Yang J, Chen L, Shang XY, et al. Roux-en-Y gastric by pass-induced perturbative changes in microbial communities and metabolic pathways in rats[J]. Front Microbiol, 2022, 13: 1034839.doi:10.3389/fmicb.2022.1034839.
[5]	Billmann F, El Shishtawi S, Bruckner T, et al. Combined non-alcoholic fatty liver disease and type 2 diabetes in severely obese patients-medium term effects of sleeve gastrectomy versus Roux-en-Y-gastric bypass on disease markers[J]. Hepatobiliary Surg Nutr, 2022, 11: 795-807.
[6]	Stenberg E, Ottosson J, Cao Y, et al. Cardiovascular and diabetes outcomes among patients with obesity and type 2 diabetes after metabolic bariatric surgery or glucagon-like peptide 1 receptor agonist treatment[J]. Br J Surg, 2024, 111:znae221.doi:10.1093/bjs/znae221.
[7]	O′neill L, Pandya V, Grigoryan Z, et al. Effects of milkfat on the gut microbiome of patients after bariatric surgery, a pilot study[J]. Obes Surg, 2022, 32:480-488.
[8]	Ke Z, Lu Z, Li F, et al. Gut microbiota alterations induced by Roux-en-Y gastric bypass result in glucose-lowering by enhancing intestinal glucose excretion[J]. Gut Microbes, 2025, 17:2473519.doi:10.1080/19490976.2025.2473519.
[9]	Sandoval DA, Patti ME. Glucose metabolism after bariatric surgery: implications for T2DM remission and hypoglycaemia[J]. Nat Rev Endocrinol, 2023, 19:164-176.
[10]	Alqahtani SJ, Alfawaz HA, Moubayed NMS, et al. Bariatric surgery as treatment strategy of obesity in saudi people: effects of gut microbiota[J]. Nutrients, 2023, 15:361. doi:10.3390/nu15020361. doi:10.3390/nu15020361.
[11]	Chamarande J, Cunat L, Pavlov N, et al. Parabacteroides distasonis properties linked to the selection of new biotherapeutics[J]. Nutrients, 2022, 14:4176.doi: 10.3390/nu14194176.
[12]	Gomez-Arango LF, Barrett HL, Wilkinson SA, et al. Low dietary fiber intake increases Collinsella abundance in the gut microbiota of overweight and obese pregnant women[J]. Gut Microbes, 2018, 9:189-201.
[13]	Wang T, Yan H, Lu Y, et al. Anti-obesity effect of Lactobacillus rhamnosus LS-8 and Lactobacillus crustorum MN047 on high-fat and high-fructose diet mice base on inflammatory response alleviation and gut microbiota regulation[J]. Eur J Nutr, 2020, 59:2709-2728
[14]	Cani PD, Hul MV. Gut microbiota in overweight and obesity: crosstalk with adipose tissue[J]. Nat Rev Gastroenterol Hepatol, 2024, 21:164-183.
[15]	Ha CWY, Martin A, Sepich-Poore GD, et al. Transloca-tion of viable gut microbiota to mesenteric adipose drives formation of creeping fat in humans[J]. Cell, 2020, 183:666-683.e17.
[16]	Wang Y, Wang M, Chen J, et al. The gut microbiota reprograms intestinal lipid metabolism through long noncoding RNA Snhg9[J]. Science, 2023, 381:851-857.
[17]	Newman NK, Zhang Y, Padiadpu J, et al. Reducing gut microbiome-driven adipose tissue inflammation alleviates metabolic syndrome[J]. Microbiome, 2023, 11:208. doi:10.1186/s40168-023-01637-4.
[18]	Clausen MR, Mortensen PB. Kinetic studies on colonocyte metabolism of short chain fatty acids and glucose in ulcerative colitis[J]. Gut, 1995; 37:684-689.
[19]	Hee BVD, Wells JM. Microbial regulation of host physiology by short-chain fatty acids[J]. Trends Microbiol, 2021, 29:700-712.
[20]	Dalile B, Oudenhove LV, Vervliet B, et al. The role of short-chain fatty acids in microbiota-gut-brain communication[J]. Nat Rev Gastroenterol Hepatol, 2019, 16:461-478.
[21]	Kulkarni DH, Rusconi B, Floyd AN, et al. Gut microbiota induces weight gain and inflammation in the gut and adipose tissue independent of manipulations in diet, genetics, and immune development[J]. Gut Microbes, 2023, 15:2284240. doi:10.1080/19490976.2023.2284240.
[22]	Zhao X, Qiu Y, Liang L, et al. Interkingdom signaling between gastrointestinal hormones and the gut microbiome[J]. Gut Microbes, 2025, 17:2456592.doi:10.1080/19490976.2023.2284240.
[23]	Susarla SM, Fiehn O, Thiele I, et al. Microbiome-derived metabolites in early to mid-pregnancy and risk of gestational diabetes: a metabolome-wide association study[J]. BMC Med, 2024, 22:449.doi 10.1186/s12916-024-03606-6.
[24]	Yuan X, Chen R, Mccormick KL, et al. The role of the gut microbiota on the metabolic status of obese children[J]. Microb Cell Fact, 2021, 20:53. doi:10.1186/s12934-021-01548-9.
[25]	Yang CX, Lan RT, Zhao LJ, et al. Prevotella copri alleviates hyperglycemia and regulates gut microbiota and metabolic profiles in mice[J]. mSystems, 2024, 9:e0053224.doi:10.1128/msystems.00532-24.

肠道菌群与代谢手术治疗肥胖及其相关代谢性疾病的研究进展

Research progress on gut microbiota and metabolic surgery for the treatment of obesity and related metabolic diseases

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 25

相关文章 15

编辑推荐

Metrics

本文评价

[1]	孙清怡, 陈果, 符晓, 孙海建, 陆清波. 肠道菌群紊乱与糖尿病心肌病[J]. 基础医学与临床, 2026, 46(1): 129-133.
[2]	赵翠娟, 敖民, 武文博, 李妍华. 高脂饮食加重小鼠肠易激综合征肠屏障损伤[J]. 基础医学与临床, 2025, 45(8): 1022-1027.
[3]	向韵瑄, 常晓悦. 肥胖促进哮喘发作的研究进展[J]. 基础医学与临床, 2025, 45(8): 1103-1107.
[4]	朱倩梅, 李清扬, 车璐, 黄宇光. 疾病相关的肠道菌群微生态在肺损伤形成的机制研究[J]. 基础医学与临床, 2025, 45(5): 681-685.
[5]	胡艳敏, 彭丽娜, 杨勇, 向韵瑄, 常晓悦. Pleckstrin同源域家族A成员1在代谢性疾病中的作用[J]. 基础医学与临床, 2025, 45(2): 268-272.
[6]	刘怡铭, 陈文杰, 史雨晨, 柳景华. 饮食、肠道菌群与血管钙化[J]. 基础医学与临床, 2025, 45(2): 154-159.
[7]	孙晓平, 陈敏. 儿童肥胖与疾病的研究进展[J]. 基础医学与临床, 2025, 45(11): 1491-1495.
[8]	加孜热亚·再依拿提, 李素丽, 张凯迪, 马福慧, 马国英, 郭艳英. 桥本甲状腺炎中辅助T细胞及其细胞因子与腹型肥胖相关[J]. 基础医学与临床, 2024, 44(8): 1120-1125.
[9]	侯楠, 刘源, 高俊, 王晶, 袁萌. 全血NPM1、MCP-1和肠道菌群与胃癌进展及预后相关[J]. 基础医学与临床, 2024, 44(8): 1137-1142.
[10]	岳玲玲, 王梓潓, 李小芹, 李利锋, 张万存, 于志丹. 肠道菌群代谢物次级胆汁酸调控宿主免疫功能[J]. 基础医学与临床, 2024, 44(6): 887-891.
[11]	丁宝锋, 王小爽, 王芳, 余佳. 肥胖模型小鼠肝脏的病理变化及代谢组分析[J]. 基础医学与临床, 2024, 44(5): 699-704.
[12]	张沥元, 杜函泽, 潘慧. 治疗下丘脑性肥胖的药物研究进展[J]. 基础医学与临床, 2024, 44(5): 729-732.
[13]	何昀, 肖力, 曹娟, 刘志刚, 罗威耀. 奥美拉唑联合不同益生菌调节肠道菌群减轻小儿功能性消化不良[J]. 基础医学与临床, 2024, 44(2): 219-224.
[14]	卢慧莹, 王建国. 下调去甲基化酶FTO抑制人肝癌细胞系HepG2增殖[J]. 基础医学与临床, 2024, 44(2): 185-191.
[15]	廖镇城, 杨思懿, 吴平安. 提高m⁶A去甲基化酶FTO表达抑制鼻咽癌细胞增殖[J]. 基础医学与临床, 2024, 44(1): 57-62.